Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: A 12-week open-label, multicenter trial

Vincenzo Mirone, Alessandro Palmieri, Domenico Cucinotta, Fabio Parazzini, Patrizia Morelli, Carlo Bettocchi, Ferdinando Fusco, Francesco Montorsi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim. To evaluate the efficacy, safety, and tolerability of a flexible-dose regimen of vardenafil in a community-based population of men with erectile dysfunction (ED). Methods. This was a 12-week, open-label, flexible-dose, multicenter study of unselected men with ED of diverse origins and severity. Unlike previous studies, prostatectomy-induced ED and previous unresponsiveness to sildenafil were not exclusion criteria. After 4 weeks of treatment with 10 mg of vardenafil, the dose could be continued or titrated to 5 mg or 20 mg, depending on efficacy and tolerability. After 8 weeks, another dose change was possible. Efficacy was assessed with International Index of Erectile Function erectile function (IIEF-EF) domain scores, diary questions of the Sexual Encounter Profile (SEP), and a global assessment question (GAQ) about erection improve-ment during the previous 4 weeks. Results. Safety was evaluated in 497 patients, and 480 were suitable for intention-to-treat analysis. After 12 weeks of treatment, the mean per patient rate of successful intercourse, defined by an affirmative response to SEP questions 1-3, was 72%, and was related to age and ED duration. The overall success rate increased from 66% at week 4 to 77% at week 12. The mean IIEF-EF domain score of the whole population increased from 17.2 (baseline) to 24.4 (endpoint). At week 12, the best scores were obtained by patients taking 5 mg and 10 mg. At week 12, GAQ scores showed improved erection in 97.4%, 94.8%, and 78.8% of patients in the 5 mg, 10 mg, and 20 mg group, respectively. Safety was excellent: no serious drug-related event was reported, and only 2.2% of patients discontinued treatment because of side-effects. Conclusions. Vardenafil was effective and well tolerated in this community-based ED population that is truly representative of the general ED population. Dose titration meets the patient's needs and optimizes clinical outcome.

Original languageEnglish
Pages (from-to)842-847
Number of pages6
JournalJournal of Sexual Medicine
Volume2
Issue number6
DOIs
Publication statusPublished - Nov 2005

Fingerprint

compound A 12
Erectile Dysfunction
Multicenter Studies
Population
Safety
Intention to Treat Analysis
Prostatectomy
Vardenafil Dihydrochloride
Therapeutics
Pharmaceutical Preparations

Keywords

  • Erectile Dysfunction
  • Global Assessment Question
  • International Index of Erectile Function
  • Vardenafil

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynaecology

Cite this

Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction : A 12-week open-label, multicenter trial. / Mirone, Vincenzo; Palmieri, Alessandro; Cucinotta, Domenico; Parazzini, Fabio; Morelli, Patrizia; Bettocchi, Carlo; Fusco, Ferdinando; Montorsi, Francesco.

In: Journal of Sexual Medicine, Vol. 2, No. 6, 11.2005, p. 842-847.

Research output: Contribution to journalArticle

Mirone, Vincenzo ; Palmieri, Alessandro ; Cucinotta, Domenico ; Parazzini, Fabio ; Morelli, Patrizia ; Bettocchi, Carlo ; Fusco, Ferdinando ; Montorsi, Francesco. / Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction : A 12-week open-label, multicenter trial. In: Journal of Sexual Medicine. 2005 ; Vol. 2, No. 6. pp. 842-847.
@article{49d04cb44d43440a915d4d69c419ddc2,
title = "Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: A 12-week open-label, multicenter trial",
abstract = "Aim. To evaluate the efficacy, safety, and tolerability of a flexible-dose regimen of vardenafil in a community-based population of men with erectile dysfunction (ED). Methods. This was a 12-week, open-label, flexible-dose, multicenter study of unselected men with ED of diverse origins and severity. Unlike previous studies, prostatectomy-induced ED and previous unresponsiveness to sildenafil were not exclusion criteria. After 4 weeks of treatment with 10 mg of vardenafil, the dose could be continued or titrated to 5 mg or 20 mg, depending on efficacy and tolerability. After 8 weeks, another dose change was possible. Efficacy was assessed with International Index of Erectile Function erectile function (IIEF-EF) domain scores, diary questions of the Sexual Encounter Profile (SEP), and a global assessment question (GAQ) about erection improve-ment during the previous 4 weeks. Results. Safety was evaluated in 497 patients, and 480 were suitable for intention-to-treat analysis. After 12 weeks of treatment, the mean per patient rate of successful intercourse, defined by an affirmative response to SEP questions 1-3, was 72{\%}, and was related to age and ED duration. The overall success rate increased from 66{\%} at week 4 to 77{\%} at week 12. The mean IIEF-EF domain score of the whole population increased from 17.2 (baseline) to 24.4 (endpoint). At week 12, the best scores were obtained by patients taking 5 mg and 10 mg. At week 12, GAQ scores showed improved erection in 97.4{\%}, 94.8{\%}, and 78.8{\%} of patients in the 5 mg, 10 mg, and 20 mg group, respectively. Safety was excellent: no serious drug-related event was reported, and only 2.2{\%} of patients discontinued treatment because of side-effects. Conclusions. Vardenafil was effective and well tolerated in this community-based ED population that is truly representative of the general ED population. Dose titration meets the patient's needs and optimizes clinical outcome.",
keywords = "Erectile Dysfunction, Global Assessment Question, International Index of Erectile Function, Vardenafil",
author = "Vincenzo Mirone and Alessandro Palmieri and Domenico Cucinotta and Fabio Parazzini and Patrizia Morelli and Carlo Bettocchi and Ferdinando Fusco and Francesco Montorsi",
year = "2005",
month = "11",
doi = "10.1111/j.1743-6109.2005.00138.x",
language = "English",
volume = "2",
pages = "842--847",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction

T2 - A 12-week open-label, multicenter trial

AU - Mirone, Vincenzo

AU - Palmieri, Alessandro

AU - Cucinotta, Domenico

AU - Parazzini, Fabio

AU - Morelli, Patrizia

AU - Bettocchi, Carlo

AU - Fusco, Ferdinando

AU - Montorsi, Francesco

PY - 2005/11

Y1 - 2005/11

N2 - Aim. To evaluate the efficacy, safety, and tolerability of a flexible-dose regimen of vardenafil in a community-based population of men with erectile dysfunction (ED). Methods. This was a 12-week, open-label, flexible-dose, multicenter study of unselected men with ED of diverse origins and severity. Unlike previous studies, prostatectomy-induced ED and previous unresponsiveness to sildenafil were not exclusion criteria. After 4 weeks of treatment with 10 mg of vardenafil, the dose could be continued or titrated to 5 mg or 20 mg, depending on efficacy and tolerability. After 8 weeks, another dose change was possible. Efficacy was assessed with International Index of Erectile Function erectile function (IIEF-EF) domain scores, diary questions of the Sexual Encounter Profile (SEP), and a global assessment question (GAQ) about erection improve-ment during the previous 4 weeks. Results. Safety was evaluated in 497 patients, and 480 were suitable for intention-to-treat analysis. After 12 weeks of treatment, the mean per patient rate of successful intercourse, defined by an affirmative response to SEP questions 1-3, was 72%, and was related to age and ED duration. The overall success rate increased from 66% at week 4 to 77% at week 12. The mean IIEF-EF domain score of the whole population increased from 17.2 (baseline) to 24.4 (endpoint). At week 12, the best scores were obtained by patients taking 5 mg and 10 mg. At week 12, GAQ scores showed improved erection in 97.4%, 94.8%, and 78.8% of patients in the 5 mg, 10 mg, and 20 mg group, respectively. Safety was excellent: no serious drug-related event was reported, and only 2.2% of patients discontinued treatment because of side-effects. Conclusions. Vardenafil was effective and well tolerated in this community-based ED population that is truly representative of the general ED population. Dose titration meets the patient's needs and optimizes clinical outcome.

AB - Aim. To evaluate the efficacy, safety, and tolerability of a flexible-dose regimen of vardenafil in a community-based population of men with erectile dysfunction (ED). Methods. This was a 12-week, open-label, flexible-dose, multicenter study of unselected men with ED of diverse origins and severity. Unlike previous studies, prostatectomy-induced ED and previous unresponsiveness to sildenafil were not exclusion criteria. After 4 weeks of treatment with 10 mg of vardenafil, the dose could be continued or titrated to 5 mg or 20 mg, depending on efficacy and tolerability. After 8 weeks, another dose change was possible. Efficacy was assessed with International Index of Erectile Function erectile function (IIEF-EF) domain scores, diary questions of the Sexual Encounter Profile (SEP), and a global assessment question (GAQ) about erection improve-ment during the previous 4 weeks. Results. Safety was evaluated in 497 patients, and 480 were suitable for intention-to-treat analysis. After 12 weeks of treatment, the mean per patient rate of successful intercourse, defined by an affirmative response to SEP questions 1-3, was 72%, and was related to age and ED duration. The overall success rate increased from 66% at week 4 to 77% at week 12. The mean IIEF-EF domain score of the whole population increased from 17.2 (baseline) to 24.4 (endpoint). At week 12, the best scores were obtained by patients taking 5 mg and 10 mg. At week 12, GAQ scores showed improved erection in 97.4%, 94.8%, and 78.8% of patients in the 5 mg, 10 mg, and 20 mg group, respectively. Safety was excellent: no serious drug-related event was reported, and only 2.2% of patients discontinued treatment because of side-effects. Conclusions. Vardenafil was effective and well tolerated in this community-based ED population that is truly representative of the general ED population. Dose titration meets the patient's needs and optimizes clinical outcome.

KW - Erectile Dysfunction

KW - Global Assessment Question

KW - International Index of Erectile Function

KW - Vardenafil

UR - http://www.scopus.com/inward/record.url?scp=28444499294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444499294&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2005.00138.x

DO - 10.1111/j.1743-6109.2005.00138.x

M3 - Article

C2 - 16422808

AN - SCOPUS:28444499294

VL - 2

SP - 842

EP - 847

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 6

ER -